2B3-101


Protocolnummer:
Gesloten

Ziekenhuizen:
NKI / A.v.L ziekenhuis Amsterdam
VU Medisch Centrum Amsterdam

Titel:
An open-label Phase1/11a dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.

Behandeling:

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: pathologically comfirmed advanced, recurrent melanoma with evidence of brain metastases that are refractory to standard therapy, Brain metastases may be stable, progressive, symptomatic or asymptomatic, stable or decreasing dosages of steroids 7 days prior to baseline MRI, newly diagnosed, untreated brain metastases which per team decision do not require immeadiate radiotherapy or surgery, no evidence of cognitive impairment, life expectancy of at least 8 weeks.

Contactpersoon:

Alle trials